Antibody

612개 · ADC 882 · Antibody 4071 · CGT 2714 · 자동 수집 갱신 권장 · 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved612 programs

데이터 갱신 주기입니다. 갱신 대기 7,666개 보기 · Curated Core는 주간 자동 동기화됩니다.

AntibodyLimited DatastaleEli Lilly and CompanyPhase 1

IMC-1121B (Ramucirumab, Ramucirumab (IMC-1121B))

Colorectal Carcinoma · Colorectal Carcinoma

#ColorectalCarcinoma#Antibody#Phase1#monoclonal-antibody#Eli
Trials 1Status Active
AntibodyLimited DatastaleEli Lilly and CompanyPhase 2

Ramucirumab DP (Ramucirumab DP)

Carcinoma of Urinary Tract; Urethral Carcinoma · Carcinoma of Urinary Tract

#CarcinomaofUrinaryTract#Antibody#Phase2#monoclonal-antibody#UrethralCarcinoma+1
Trials 1Status Active
AntibodyLimited DatastaleZhejiang Cancer HospitalPhase 2

Recombinant human adenovirus type 5＋Camrelizumab (Recombinant human adenovirus type 5＋Camrelizumab)

Uterine Cervical Neoplasms; Oncolytic Virotherapy · Uterine Cervical Neoplasms

#UterineCervicalNeoplasms#Antibody#Phase2#monoclonal-antibody#OncolyticVirotherapy+1
Trials 1Status Active
AntibodyLimited DatastaleTianjin Medical University Canc…Phase 2

Regorafenib and tislelizumab (Regorafenib and tislelizumab)

Hepatocellular Carcinoma · Hepatocellular Carcinoma

#HepatocellularCarcinoma#Antibody#Phase2#monoclonal-antibody#Tianjin
Trials 1Status Recruiting
AntibodyLimited DatastaleAsan Medical CenterPhase 2

nivolumab (Opdivo, Regorafenib/Nivolumab)

Carcinoma, Hepatocellular; Hepatoma · Carcinoma, Hepatocellular

#CarcinomaHepatocellular#Antibody#Phase2#monoclonal-antibody#Carcinoma+3
Trials 1Status Active
AntibodyLimited DatastaleLoyola UniversityPhase 2

infliximab (Remicaide, Remicaide (infliximab))

Toxic Epidermal Necrolysis · Toxic Epidermal Necrolysis

#ToxicEpidermalNecrolysis#Antibody#Phase2#monoclonal-antibody#Loyola
Trials 1Status Discontinued
AntibodyLimited DatastaleUniversity of Alabama at Birmin…Phase 1

Retifanlimab, INCAGN02385, INCAGN02390 (Retifanlimab, INCAGN02385, INCAGN02390)

Diffuse Large B Cell Lymphoma; Lymphoma, B-Cell · Diffuse Large B Cell Lymphoma

#DiffuseLargeBCellLymphoma#Antibody#Phase1#monoclonal-antibody#Lymphoma+2
Trials 1Status Discontinued
AntibodyLimited DatastaleAmgenPhase 3

Romosozumab (Romosozumab)

Postmenopausal Osteoporosis · Postmenopausal Osteoporosis

#PostmenopausalOsteoporosis#Antibody#Phase3#monoclonal-antibody#Amgen
Trials 1Status Active
AntibodyLimited DatastaleSanofiPhase 2

Tusamitamab ravtansine (SAR408701, SAR408701 (Tusamitamab ravtansine))

Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC) · Non-squamous Non-small-cell Lung Cancer

#Non-squamousNon-small-cellLungCa#Antibody#Phase2#monoclonal-antibody#Sanofi
Trials 1Status Discontinued
AntibodyLimited DatastaleSamsung Bioepis Co., Ltd.Approved

Adalimumab Biosimilar (SB5, SB5 (Adalimumab Biosimilar))

Plaque Psoriasis · Plaque Psoriasis

#PlaquePsoriasis#Antibody#Approved#monoclonal-antibody#Samsung
Trials 1Status Active
AntibodyLimited DatastaleAbbViePhase 3

proposed biosimilar to adalimumab (SB5, SB5 (proposed biosimilar to adalimumab))

Rheumatoid Arthritis · Rheumatoid Arthritis

#RheumatoidArthritis#Antibody#Phase3#monoclonal-antibody#AbbVie
Trials 1Status Active
AntibodyLimited DatastaleInstitut Cancerologie de l'OuestPhase 2

durvalumab (Imfinzi, SBRT + Durvalumab)

Node; Prostate; Bone Metastases · Node; Prostate

#NodeProstate#Antibody#Phase2#monoclonal-antibody#Node+3
Trials 1Status Recruiting
AntibodyLimited DatastaleZibo Municipal HospitalPhase 2

SBRT combined with Tislelizumab followed by Tislelizumab (SBRT combined with Tislelizumab followed by Tislelizumab)

NSCLC; Tislelizumab · FRα

#FR#Antibody#Phase2#monoclonal-antibody#NSCLC+2
Trials 1Status Recruiting
AntibodyLimited DatastaleRochePhase 2

SC0191 + Bevacizumab (SC0191 + Bevacizumab)

Metastatic Colorectal Cancer · Metastatic Colorectal Cancer

#MetastaticColorectalCancer#Antibody#Phase2#monoclonal-antibody#Roche
Trials 1Status Active
AntibodyLimited DatastaleNational Cancer Centre, Singapo…Phase 2

atezolizumab (Tecentriq, SIRT-Y90 with Atezolizumab + Bevacizumab)

Locally Advanced Hepatocellular Carcinoma · Locally Advanced Hepatocellular Carcinom

#LocallyAdvancedHepatocellularCar#Antibody#Phase2#monoclonal-antibody#National
Trials 1Status Recruiting
AntibodyLimited DatastaleHuashan HospitalPreclinical

Satralizumab (Satralizumab)

Neuromyelitis Optica Spectrum Disorders (NMOSD) · Neuromyelitis Optica Spectrum Disorders

#NeuromyelitisOpticaSpectrumDisor#Antibody#Preclinical#monoclonal-antibody#Huashan
Trials 1Status Recruiting
AntibodyLimited DatastaleNektar TherapeuticsPhase 2

nivolumab (Opdivo, Schedule Finding Triplet: Combination of NKTR-214+ nivolumab+ ipilimumab)

Melanoma; Renal Cell Carcinoma · HER2

#HER2#Antibody#Phase2#monoclonal-antibody#Melanoma+2
Trials 1Status Active
AntibodyLimited DatastaleAstraZenecaPhase 2

durvalumab (Imfinzi, Selumetinib + ZEN-3694 ± Durvalumab)

MPNST; NF1 · MPNST

#MPNST#Antibody#Phase2#monoclonal-antibody#NF1+1
Trials 1Status Recruiting
AntibodyLimited DatastaleEastern Hepatobiliary Surgery H…Phase 3

sequential group (Sequential treatment of bevacizumab combined with atezolizumab, Sequential treatment of bevacizumab combined with atezolizumab (sequential group))

HCC - Hepatocellular Carcinoma · HCC - Hepatocellular Carcinoma

#HCC-HepatocellularCarcinoma#Antibody#Phase3#monoclonal-antibody#Eastern
Trials 1Status Recruiting
AntibodyLimited DatastaleRochePhase 3

Serplulimab combined with bevacizumab and first-line chemotherapy (Serplulimab combined with bevacizumab and first-line chemotherapy)

Non-small Cell Lung Cancer Stage II; Bevacizumab · Non-small Cell Lung Cancer Stage II

#Non-smallCellLungCancerStageII#Antibody#Phase3#monoclonal-antibody#Bevacizumab+1
Trials 1Status Active

24 / 31 pages

← PreviousNext →